Additional information
| Raw Material | 0,75mg TB4 + 0,6mg MGF + 0,75mg Ipamorelin |
|---|---|
| Water Retention | Depends on the specific peptide, some may cause minimal water retention |
| Hepatotoxicity | Typically low, but depends on the peptide and dosage |
| Lab Test | Specific tests for individual peptides, not a standard panel |
| Also known as | Peptide therapy, peptide supplements |
| Blood pressure | Generally minimal impact, but dependent on specific peptide and overall health |
| Trade name | Varies by peptide and manufacturer |
| Storage conditions | Typically requires refrigeration, avoid direct light |
| Chemical name | Various peptides |
| Formula | Variable |
| Substance class | Peptides |
| Main action | Tissue repair and growth, hormone regulation |
| Half-life | Varies depending on the peptide structure, typically a few minutes to hours |
| Dosage (medical) | Varies depending on specific peptide and condition, consult healthcare provider |
| Dosage (sports) | Varies, often higher than medical dosages, consult a professional |
| Effects | Improved recovery, increased muscle mass, enhanced performance |
| Side effects | Potential for hormonal imbalance, risk of allergic reactions, possible irritation at injection sites |
| Use in sports | Common in bodybuilding and athletics for performance enhancement |
| Manufacturer | Lifetech Labs |
| Packing | 10 VIALS (2.1MG PER VIAL) |
T3 Sciroxx
Euthyrox (T4) 150 mcg Merckgroup
Balkan Pharma Strombafort 50 mg 60 Tabletten
Sibutramine Magnus Pharmaceuticals
Hardcore - xDrop Omega Lab
CLENBULL BULL PHARMA
Lasix Sanofi
Balkan Pharma Clenbuterol 40 mcg 60 Tabletten
Clenbuterol 40mcg DNA
Clenbolic Clenbuterol Hydrochlorid Cooper Pharma
Clenbuterolhydrochlorid Nouveaux Ltd
Clomid 50 mg Magnus Pharmaceuticals
Norvacs 5 mg Pfizer
Cabaser 1 mg 20 Tabletten
Balkan Pharma Halotestin 10mg 100 Tabletten
Anapolon 50 mg 20 Tabletten
LACIPIL 4 mg Glaxosmithkline
Seretide Disckus (Advair) 250 mcg Glaxosmithkline
FUCIDIN 500 mg Abdi Ibragim 

Reviews
There are no reviews yet.